Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 4 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.


Player Avatar OKwarrior (45.95) Submitted: 6/9/2014 1:33:24 AM : Outperform Start Price: $35.54 ACOR Score: +7.00

biotech w/ actual cash flow and no negatives on the EPS. Valuations are pretty high, but that is because of the hope for the big score on MS drugs.

Featured Broker Partners